Autoantibodies and B cells are drivers of progressive autoimmune diseases, but targeting B cells or plasma cells alone is not sufficient to address them. Earendil Labs has presented data on HXN-1031, a novel T-cell engager targeting both CD19 and B-cell maturation protein (BCMA).
Alaunos Therapeutics Inc. has announced early data from two non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN-1003, the company’s lead small-molecule drug candidate for treating obesity and related conditions, such as metabolic dysfunction-associated steatotic liver disease (MASLD).
CAR T cells have been groundbreaking for the treatment of B-cell cancers. But 8 years after Kymriah (tisagenlecleucel, Novartis AG) became the first CAR T-cell therapy to be approved, there are no CAR Ts approved for solid tumors.
Prospect Therapeutics Inc. has synthesized new substituted tricyclic derivatives acting as tyrosine-protein kinase JAK1 and non-receptor tyrosine-protein kinase TYK2 inhibitors.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has divulged new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an EGFR-targeting moiety via a linker.
G-protein coupled receptor 68 (GPR68) is an acid-sensing protein receptor that has been implicated in inflammatory bowel disease (IBD) pathogenesis by its modulation of the inflammatory response and fibrosis.
RSS
